



GIACONDA APPOINTS NEW COMPANY SECRETARY

Sydney, Australia. 3 September 2007. Giaconda Limited (ASX: GIA) today announced that David Fischl has been appointed Company Secretary. This appointment takes effect as of 31st August 2007.

David Fischl, BCom, LLB (UNSW) is a partner at Hicksons Lawyers and practices commercial and corporate law with a focus on the technology area. David is currently completing the Graduate Diploma of Applied Corporate Governance through the Chartered Secretaries of Australia. Mr Fischl was Company Secretary of Giaconda prior to its listing on the ASX from July 2004 to September 2005.

"We are delighted to have David back at Giaconda. Due to his previous involvement with us he knows the Company well and we look forward to the benefits of his expertise in the future," said Patrick McLean, CEO of Giaconda.

"I would also like to take this opportunity to let our investors know that a new research report on the Company written by Intersuisse Ltd is now available on our website."

About Giaconda Limited

Giaconda Limited is a biotechnology company involved in developing and licensing innovative and cost effective medical therapies in the field of gastroenterology. Giaconda's products are targeted towards the treatment of serious conditions that are not adequately addressed by any existing therapy. In this way, Giaconda's products are intended to satisfy these significant unmet medical needs of the gastrointestinal market. The Giaconda portfolio consists of five products, all of which are novel combinations of known compounds. Giaconda has two lead products, Myoconda[®] for the treatment of MAP (*Mycobacterium avium paratuberculosis*) infection in Crohn's Disease and Heliconda[®] for the treatment of resistant *Helicobacter pylori* infection.

For more information please visit www.giacondalimited.com

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

CONTACTS:

Company	Media & Investor Relations
Patrick McLean – Chief Executive Officer	Fay Weston – Talk Biotech
T: +61 (0)2 9370 0069	T: +61 422 206 036
E: pmclean@giacondalimited.com	E: fayweston@talkbiotech.com.au

GIACONDA LIMITED

Ground Floor, 44 East Street, Five Dock NSW 2046 Phone: [612] 9370 0069 Fax: [612] 9712 1469
email: info@giacondalimited.com ABN 68 108 088 517 www.giacondalimited.com